@article {7985,
	title = {Combined use of 99mTc-sestamibi and 99mTc-V-DMSA in the assessment of chemotherapy effectiveness in patients with multiple myeloma},
	journal = {Journal of Nuclear Medicine},
	volume = {46},
	year = {2005},
	note = {Cited By :8Export Date: 21 February 2017},
	month = {2005},
	pages = {978 - 982},
	abstract = {This study determined the role of the combined use of 99mTc- sestamibi and 99mTc-pentavalent dimercaptosuccinic acid (V-DMSA) scintigraphy in evaluating the effectiveness of chemotherapy in patients with multiple myeloma. Methods: In 20 patients with multiple myeloma who had received or were receiving chemotherapy, 99mTc-sestamibi and 99mTc-V-DMSA scanning was performed to evaluate the effectiveness of chemotherapy. Results: In group A (11 patients with active disease), 42 99mTc-sestamibi-positive lesions were found. Thirty-seven of those lesions were also positive for 99mTc-V-DMSA uptake, as were 16 additional lesions (nonactive) (NAL). Thus, in group A, the total number of positive lesions (TPL) detected was 58 and the NAL/TPL ratio was 16:58. In group B (9 patients in remission), 5 99mTc-sestamibi-positive lesions were found. A further 22 lesions were also positive for 99mTc-V-DMSA uptake. Thus, in group B, the NAL/TPL ratio was 22:27. Therefore, the NAL/TPL ratios considered to represent effectively treated lesions were 27.6\% and 81.5\% for groups A and B, respectively. Conclusion: Combined use of the 2 agents allows the effectiveness of chemotherapy to be evaluated through a comparison of NAL and TPL multiple myeloma lesions even in the absence of a baseline study.},
	keywords = {99mTc-MIBI, 99mTc-V-DMSA, Chemotherapy, multiple myeloma, Treatment},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-23044443687\&partnerID=40\&md5=f27deca7addece9711ccf911e900eb78},
	author = {Koutsikos, J. and Athanasoulis, T. and Anagnostopoulos, A. and Velidaki, A. and Passadi, M. and Dimopoulos, M.A. and Zerva, C.}
}
